FDG-PET and CT features of non-small cell lung cancer based on tumor type

International Journal of Molecular Medicine

Volumn 19, Issue 3, 2007, Pages 495-499

  Aquino, Suzanne L ^a   Halpern, Elkan F ^a   Kuester, Landon B ^a   Fischman, Alan J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bronchioloalveolar; Carcinoma; Carcinoma non small cell lung; Computerized emission tomography; Lung neoplasm

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33947523843     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.19.3.495     Document Type: Article

References (28)

1. Gupta NC, Maloof J and Gunel E: Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 37: 943-948, 1996.
2. Gupta NC, Frank AR, Dewan NA, et al: Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 184: 441-444, 1992.
3. Dewan NA, Shehan CJ, Reeb SD, Gobar LS, Scott WJ and Ryschon K: Likelihood of malignancy in a solitary pulmonary nodule: comparison of Bayesian analysis and results of FDG-PET scan. Chest 112: 416-422, 1997.
4. Patz EF Jr, Lowe VJ, Hoffman JM, et al: Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188: 487-490, 1993.
5. Herder GJ, Golding RP, Hoekstra OS, et al: The performance of (18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 31: 1231-1236, 2004.
6. Higashi K, Ueda Y, Seki H, et al: Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39: 1016-1020, 1998.
7. Heyneman LE and Patz EF: PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 38: 261-266, 2002.
8. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V and Goodman PC: Evaluation of primary pulmonary carcinoid tumors using FDG PET. Am J Roentgenol 170: 1369-1373, 1998.
9. Kim BT, Kim Y, Lee KS, et al: Localized form of bronchioloalveolar carcinoma: FDG PET findings. Am J Roentgenol 170: 935-939, 1998.
10. Marom EM, Sarvis S, Herndon JE 2nd and Patz EF Jr: T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 223: 453-459, 2002.
11. Libby DM, Smith JP, Altorki NK, Pasmantier MW, Yankelevitz D and Henschke CI: Managing the small pulmonary nodule discovered by CT. Chest 125: 1522-1529, 2004.
12. Nakata M, Saeki H, Takata I, et al: Focal ground-glass opacity detected by low-dose helical CT. Chest 121: 1464-1467, 2002.
13. Erasmus JJ, Connolly JE, McAdams HP, Roggli VL: Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 20: 43-58, 2000.
14. Gupta NC, Graeber GM, Rogers JS 2nd and Bishop HA: Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 229: 286-291, 1999.
15. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343: 254-261, 2000.
16. Berlangieri SU, Scott AM, Knight SR, et al: F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg 16 (Suppl 1): S25-S30, 1999.
17. Henschke CI, Yankelevitz DF, Mirtcheva R, McGuinness G, McCauley D and Miettinen OS: CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules. Am J Roentgenol 178: 1053-1057, 2002.
18. Golshani-Hebroni SG and Bessman SP: Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr 29: 331-338, 1997.
19. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A and Wahl RL: Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 40: 556-565, 1999.
20. Mathupala SP, Rempel A and Pedersen PL: Glucose catabolism in cancer cells. J Biol Chem 270: 16918-16925, 1995.
21. Vesselle H, Schmidt RA, Pugsley JM, et al: Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6: 3837-3844, 2000.
22. Higashi K, Ueda Y, Ayabe K, et al: FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 21: 707-714, 2000.
23. Sugawara Y, Quint LE, Iannettoni MD, et al: Does the FDG uptake of primary non-small cell lung cancer predict prognosis? A Work in Progress. Clin Positron Imaging 2: 111-118, 1999.
24. Marom EM, Aloia TA, Moore MB, et al: Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 33: 99-107, 2001.
25. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE and Wolfe WG: Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 60: 1348-1352, 1995.
26. Ito T, Noguchi Y, Satoh S, Hayashi H, Inayama Y and Kitamura H: Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. Mod Pathol 11: 437-443, 1998.
27. Higashi K, Ueda Y, Sakurai A, et al: Correlation of Glut-1 glucose transporter expression with. Eur J Nucl Med 27: 1778-1785, 2000.
28. Yap CS, Schiepers C, Fishbein MC, Phelps ME and Czernin J: FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging 29: 1166-1173, 2002.